Tricida (TCDA) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS
Tricida (NASDAQ:TCDA) issued its quarterly earnings results on Thursday. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.19, Fidelity Earnings reports.
NASDAQ TCDA traded up $1.31 during trading on Friday, reaching $29.72. 102,280 shares of the stock traded hands, compared to its average volume of 106,502. Tricida has a fifty-two week low of $21.87 and a fifty-two week high of $40.10.
A number of brokerages recently issued reports on TCDA. Zacks Investment Research cut shares of Tricida from a “buy” rating to a “hold” rating in a report on Wednesday, September 26th. Cowen began coverage on shares of Tricida in a report on Monday, July 23rd. They set an “outperform” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Tricida in a report on Monday, July 23rd. They set a “neutral” rating and a $34.00 price objective for the company. Finally, Goldman Sachs Group began coverage on shares of Tricida in a report on Monday, July 23rd. They set a “neutral” rating and a $32.00 price objective for the company.
WARNING: “Tricida (TCDA) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2018/11/10/tricida-tcda-releases-quarterly-earnings-results-beats-expectations-by-0-19-eps.html.
Tricida Company Profile
Tricida, Inc, a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease.
Featured Story: Trading Strategy Examples and Plans
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.